Amylyx Pharmaceuticals (AMLX) Tax Provisions (2022 - 2025)

Amylyx Pharmaceuticals has reported Tax Provisions for 4 years, with the latest figure at -$30.4 million in Q4 2025.

• On a quarterly basis, Tax Provisions rose 52.29% year-over-year to -$30.4 million in Q4 2025; TTM through Dec 2025 was -$30.4 million, a 52.11% increase from a year earlier, with the FY2025 full-year figure at -$30.4 million, up 52.11% from the prior year.
• Tax Provisions was -$30.4 million for Q4 2025 at Amylyx Pharmaceuticals, up from -$63.7 million in the prior quarter.
• The five-year high for Tax Provisions was $2.0 million in Q4 2023, with the low at -$63.7 million in Q4 2024.
• Average Tax Provisions over 4 years is -$8.0 million, with a median of $200000.0 recorded in 2022.
• The sharpest annual moves came in 2023 and 2024: Tax Provisions soared 1314.4% in 2023, then slumped 3334.69% in 2024.
• Over 4 years, Tax Provisions stood at $574000.0 in 2022, then jumped by 243.03% to $2.0 million in 2023, then plunged by 3334.69% to -$63.7 million in 2024, then surged by 52.29% to -$30.4 million in 2025.
• The last three Tax Provisions figures came in at -$30.4 million (Q4 2025), -$63.7 million (Q4 2024), and $242000.0 (Q1 2024), per Business Quant data.